company background image
A003220 logo

Daewon Pharmaceutical KOSE:A003220 Stock Report

Last Price

₩16.21k

Market Cap

₩343.6b

7D

5.7%

1Y

8.1%

Updated

20 Jul, 2024

Data

Company Financials +

Daewon Pharmaceutical Co., Ltd.

KOSE:A003220 Stock Report

Market Cap: ₩343.6b

A003220 Stock Overview

A pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea.

A003220 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance2/6
Financial Health5/6
Dividends4/6

Daewon Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Daewon Pharmaceutical
Historical stock prices
Current Share Price₩16,210.00
52 Week High₩20,700.00
52 Week Low₩13,940.00
Beta0.46
11 Month Change13.44%
3 Month Change7.07%
1 Year Change8.07%
33 Year Change3.06%
5 Year Change17.64%
Change since IPO256.08%

Recent News & Updates

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

Jul 17
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Mar 21
There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Recent updates

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

Jul 17
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Mar 21
There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Mar 26
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?

Mar 07
Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?

Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?

Feb 18
Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Jan 31
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?

Jan 13
Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?

Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend

Dec 24
Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend

Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly

Dec 10
Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly

Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?

Nov 22
Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?

Shareholder Returns

A003220KR PharmaceuticalsKR Market
7D5.7%-0.8%-2.1%
1Y8.1%12.8%4.3%

Return vs Industry: A003220 underperformed the KR Pharmaceuticals industry which returned 12.9% over the past year.

Return vs Market: A003220 exceeded the KR Market which returned 4.3% over the past year.

Price Volatility

Is A003220's price volatile compared to industry and market?
A003220 volatility
A003220 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement4.9%
10% most volatile stocks in KR Market11.1%
10% least volatile stocks in KR Market2.2%

Stable Share Price: A003220 has not had significant price volatility in the past 3 months.

Volatility Over Time: A003220's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19581,125Seung-Ryel Baekwww.daewonpharm.com

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease.

Daewon Pharmaceutical Co., Ltd. Fundamentals Summary

How do Daewon Pharmaceutical's earnings and revenue compare to its market cap?
A003220 fundamental statistics
Market cap₩343.59b
Earnings (TTM)₩23.53b
Revenue (TTM)₩561.16b

14.6x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A003220 income statement (TTM)
Revenue₩561.16b
Cost of Revenue₩286.01b
Gross Profit₩275.16b
Other Expenses₩251.62b
Earnings₩23.53b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.11k
Gross Margin49.03%
Net Profit Margin4.19%
Debt/Equity Ratio56.9%

How did A003220 perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

27%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.